Spotlight On... Tufts pegs R&D costs at $2.6B per drug; Tigenix raises $26M; and more...

Tufts University's Center for the Study of Drug Development updated its widely cited--and oft-disputed--estimates for how much it costs to take a drug from the lab to the pharmacy, tabbing the figure at about $2.6 billion. That number, averaged from 106 randomly selected products from 10 pharma companies, is 8.5% higher than the result of Tufts' prior survey, released in 2014. More

@FierceBiotech: Corvus shoots for $80M in an IPO to support its immuno-oncology pipeline. News | Follow @FierceBiotech

@JohnCFierce: Interesting to think that pointing out what Trump got wrong could become a full-time job for the next 4 years. More | Follow @JohnCFierce

> Belgian biotech Tigenix raised about $26 million in a private placement to support its in-development treatment for bowel disease. Story

> NantKwest ($NK) said it will have to restate its last two quarterly financial disclosures after identifying an accounting error related to stock compensation for Chairman and CEO Patrick Soon-Shiong. Item

Medical Device News

@FierceMedDev: FDA loss in Vascular Solution off-label promotion case foreshadowed Amarin settlement, Artlce | Follow @FierceMedDev

@VarunSaxena2: Hmmm... all the media bumpkins can say Rubio won again. This is all you need to know.  | Follow @VarunSaxena2

@EmilyWFierce: Apple plots smartphone-based medical device application for Apple Watch. Article | Follow @EmilyWFierce

> Boston Sci wins FDA approval of ablation catheter to treat atrial flutter. Story

Pharma News

@FiercePharma: BeiGene approved to start China leg of global BTK inhibitor trial. Story | Follow @FiercePharma

@EricPFierce: Vertex, committed to continuous manufacturing, has Hovione build plant to complement the one it already has. Story | Follow @EricPFierce

@CarlyHFierce: Perrigo execs collect $2.75M in bonuses for fending off Mylan takeover. More | Follow @CarlyHFierce

> EMA puts Gilead's Zydelig under the lens after deaths crop up in trials. Article

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.